Verrica Pharmaceuticals (VRCA) Stock Statistics & Valuation Metrics

Verrica Pharmaceuticals has a market cap or net worth of $42.48M. The enterprise value is $92.02M.

Verrica Pharmaceuticals has 91.78M shares outstanding. The number of shares has decreased by -2.65% in one year.

Verrica Pharmaceuticals’s return on equity (ROE) is 7.77 and return on invested capital (ROIC) is -170.21%.

The current PE Ratio of Verrica Pharmaceuticals is -0.47. Verrica Pharmaceuticals’s PEG ratio is 0.00.

In the last 12 months, Verrica Pharmaceuticals had revenue of $7.57M and earned -$76.58M in profits. Earnings per share was -$1.61.

In the last 12 months, operating cash flow was -$60.93M and capital expenditures -$27.00K, giving a free cash flow of -$60.95M billion.

Verrica Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of

Verrica Pharmaceuticals upcoming earnings date is May 7, 2025, TBA.

Verrica Pharmaceuticals as a current ratio of 1.76, with Debt / Equity ratio of -4.66

In the past 12 months, Verrica Pharmaceuticals has paid $296.72K in taxes.

Verrica Pharmaceuticals EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.59.

Verrica Pharmaceuticals has $46.33M in cash and marketable securities with $45.94M in debt, giving a net cash position of -$390.00K billion.

Gross margin is 75.51%, with operating margin of -871.25%, and net profit margin of -1012.15%.

The average price target for Verrica Pharmaceuticals is $3.50, which is 11.43% higher than the current price. The consensus rating is Hold